21 mar: NPinvestor.com A/S: Indkaldelse til ordinær generalforsamling i N..
21 mar: Nr. 5/2019 - Nærtståendes transaktioner
21-03-2019 13:00:55

Annual General Meeting 2019 – GN Store Nord A/S

Today, GN Store Nord A/S held its annual general meeting in accordance with the agenda announced on February 27, 2019.

The report by the Board of Directors was adopted, both the Annual Report 2018 and the proposal to distribute dividends of DKK 1.35 per share of nominally DKK 4 were approved, and discharge was granted to the Board of Directors and Executive Management.

The general meeting approved the remuneration to the Board of Directors for 2019.

Per Wold-Olsen, William E. Hoover, Jr., Gitte Pugholm Aabo, Wolfgang Reim, Hélène Barnekow and Ronica Wang were re-elected to the Board of Directors by the general meeting.

Furthermore, PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was elected as new auditor for the company.

Moreover, all proposals by the Board of Directors were approved.

At the constituting board meeting held after the annual general meeting, Per Wold-Olsen was elected chairman of the Board of Directors, and William E. Hoover, Jr. was elected deputy chairman of the Board of Directors.

Per Wold-Olsen was also elected as chairman of the remuneration committee and the nomination committee. Gitte Pugholm Aabo was elected as chairman of the audit committee, and Wolfgang Reim was elected as chairman of the strategy committee.

Agenda for the annual general meeting:

a)Report by the Board of Directors on the activities of the company during the past year.
b)Submission of the audited annual report for approval.
c)Resolution of discharge to the Board of Directors and the executive management.
d)Application of profits in accordance with the approved annual report.
e)Approval of remuneration to the Board of Directors for the current financial year.
f)Election of members to the Board of Directors.
g)Election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as new auditor to serve until the company’s next annual general meeting.
h)Proposals from the Board of Directors and shareholders.
h.1Proposals from the Board of Directors.
h.1.1Proposal from the Board of Directors to authorize the Board of Directors to acquire treasury shares up to a total nominal value equivalent to 10% of the share capital, subject to a holding limit of 15% of the share capital, at the market price applicable at the time of purchase subject to a deviation of up to 10%.
h.1.2Proposal from the Board of Directors to reduce the company’s share capital by nominally DKK 13,664,456 by cancellation of treasury shares.
h.1.3Proposal from the Board of Directors to approve a new remuneration policy, including general guidelines for incentive pay.
h.2Proposals from shareholders (None).
i)Any other business.

For further information, please contact:

Investors and analysts

Peter Justesen

VP – Investor Relations & Treasury

Tel: +45 45 75 87 16

Or

Rune Sandager

Senior Manager Investor Relations 

Tel: +45 45 75 92 57

Press and the media

Lars Otto Andersen-Lange

Head of Media Relations & Corporate Public Affairs

Tel: +45 45 75 02 55

About GN Group

The GN Group is a global leader in intelligent audio solutions that let you hear more, do more and be more than you ever thought possible. Our ambitious 150-year journey has taken us from telegraph cables to radio waves and intelligent audio engineering. To celebrate our anniversary, we look to our unique competences within medical, professional and consumer audio solutions to help us continue to transform lives through the power of sound. 

GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra and BlueParrott in 100 countries. Founded in 1869, the GN Group employs 6,000 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com - and connect with us on LinkedIn, Facebook and Twitter.

Attachment

logo.png

Relateret indhold
17 apr - 
Onsdagens aktier: Coloplast faldt, men GN faldt mest
17 apr - 
Middag: Coloplast sætter sig mere end markedet efter FD..
17 apr - 
BØRSÅBNING: Coloplast sendes ned oven på USA-påbud i rø..
Relateret debat
15 apr - 
Læste på et medie at et pengeinstitut i norden have de ..
15 apr - 
Nemlig - og det er jo på et tidspunkt hvor de alle har ..
15 apr - 
Så har de taget markedsandele hver mdr. I første kvt. �..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
15 apr
GN
Nemlig - og det er jo på et tidspunkt hvor de alle har lanceret nye produkter. Så GN må bare ha' ram..
1
15 apr
GN
Så har de taget markedsandele hver mdr. I første kvt. 😜
1
15 apr
GN
Det bliver RIGTIG godt - mere godt nyt, og som håbet er det fra Resound: ------ GN fortsætter succes..
1

Episode 15 - Lars Seier Christensen ser FC Porto som model for FCK

11-04-2019 15:15:13
I denne episode er finansmanden Lars Seier Christensen gæst i studiet hos Euroinvestors Lars Christensen til en snak om investeringer i sports- og fritidsindustrien med afsæt i Lars Seier Christensens nylige investering i Parken Sport & Entertainment - virksomheden bag fodboldklubben FC København.I samtalen fremhæver Lars Seier Christensen blandt andet den portugisiske fodklub FC Porto som en mode..

Aktier/tendens: Panalpina-tal kan give DSV-fokus i rolig handelsstart

17-04-2019 07:48:02
DSV kan komme i fokus onsdag, efter at schweiziske Panalpina, som den danske transportgigant er ved at overtage, fra morgenstunden har præsenteret regnskabstal, der var bedre end ventet blandt analytikerne.I årets første kvartal nåede Panalpina en omsætning på 1,49 mia. schweizerfranc, svarende til 9,8 mia. kr., hvor der blandt analytikere adspurgt af Bloomberg News var ventet en omsætning på 1,45..

Genmab-partner leverer bedre end ventet: Darzalex skuffer lidt

16-04-2019 12:58:48
Den amerikanske medicinalvirksomhed Johnson & Johnson, der samarbejder med danske Genmab omkring salg af kræftmidlet Darzalex, har leveret et bedre end ventet regnskab for første kvartal.Til gengæld ser det globale salg af Darzalex ud til at skuffe, da det i første kvartal endte på 629 mio. dollar. Til sammenligning havde Sydbanks senioranalytiker Søren Løntoft Hansen ventet et globalt salg på 660..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

GN Store Nord A/S 328,00 -3,4% Fald i aktiekurs
GN Store Nord Ord Shs 328,00 -3,4% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. april 2019 20:23:35
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190410.2 - EUROWEB3 - 2019-04-19 20:23:35 - 2019-04-19 20:23:35 - 1 - Website: OKAY